Drugs / EB-DNK101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07627711 | Mar 2026 → Apr 2027 expected | metastatic neoplasm, pancreatic ductal adenocarcinoma | Beijing Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07480928 | Feb 2026 → Feb 2027 expected | pancreatic ductal adenocarcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-DNK101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07480928 ↗ |
| Modality | Cell therapy | “Allogeneic CAR-NK cells engineered with a dual-recognition CAR targeting MSLN and MUC1.” NCT07627711 ↗ |
| Route | Intravenous | “Administered as an IV infusion on Day 0 (dose level dependent).” NCT07480928 ↗ |
| Target | MSLN | “Allogeneic CAR-NK cells engineered with a dual-recognition CAR targeting MSLN and MUC1.” NCT07480928 ↗ |
| Target | MUC1 | “Allogeneic CAR-NK cells engineered with a dual-recognition CAR targeting MSLN and MUC1.” NCT07480928 ↗ |